Mental illness 'A Broad Overview'

Dr H Pathmanandam May 2019

Introduction

- Mental disorders are common in primary and secondary care
- Many are not recognised and not treated
- Some receive unnecessary or inappropriate treatment
- Must improve recognition and management

Mental disorders

Hierarchy of mental disorders

- Organic
- Psychotic
- Affective
- Neuroses
- Personality

Affective disorders

Depression

- Low mood
- Loss of interest or pleasure in activities
- Decreased energy or fatiguability

Cognitive symptoms

- Loss of confidence/self esteem
- Guilt
- Poor concentration
- Poor memory
- Suicidal ideation/behaviour

Biological (somatic) symptoms

- Anhedonia
- Lack of emotional response
- Early morning waking
- Diurnal mood variation
- Psychomotor retardation or agitation
- Marked loss of appetite
- Weight loss at least 5% of body weight in last month
 Loss of libido

Treatment of depression

- Stepped care model
- Wait and see
- Psychological/psychosocial interventions
- CBT
- Medication
 - SSRI
 - If ineffective switch to different class

Refractory depression

- Venlafaxine
- Lithium
- Combination of antidepressants
- Augmentation with antipsychotics

Mania

- Elevated mood, grandiose
- Increased activity, increased talkativeness
- Thought disorder
- Decreased sleep
- Disinhibited
- Reckless behaviour
- Psychotic symptoms

Management of acute mania

- Stop antidepressant
- First episode start an antipsychotic
 - Consider individual risk and side effects
 - Start low and titrate according to response
- Consider adding short-term benzodiazepine

Long term management

- If response is inadequate consider adding
 - Lithium
 - Sodium valproate
- If already on a mood stabiliser optimise treatment and then consider adding antipsychotic
- For long term treatment of bipolar affective disorder
 - Lithium
 - Sodium valproate
 - Antipsychotic

Anxiety disorders

Generalised anxiety disorder (GAD)

- 'Free-floating' anxiety
- Excessive and inappropriate worry
- Symptoms for several months
- Usually involve elements of:
 - apprehension
 - motor tension
 - autonomic overactivity

GAD: acute treatment

- Emergency benzodiazepines (max 2-4 weeks)
- CBT
- First line some SSRIs: escitalopram, paroxetine and sertraline
- Venlafaxine
- Some TCAS imipramine, clomipramine

Panic disorder (PD)

- Several severe attacks of autonomic anxiety should have occurred within a period of about 1 month
- There is no objective danger;
- Not confined to known or predictable situations
- Free from anxiety symptoms between attacks (although anticipatory anxiety is common).

PD: acute treatment

- CBT
- ? Benzodiazepines (not recommended by NICE)
- SSRIs
- TCAs (imipramine and clomipramine)
- Reboxetine

Social phobia

- There are psychological, behavioural, or autonomic symptoms of anxiety
- the anxiety must be restricted to or predominate in particular social situations
- the phobic situation is avoided whenever possible.

Social phobia: acute treatment

- CBT
- First choice SSRIs
- MAOIs

Post-traumatic stress disorder (PTSD)

- Onset follows the trauma with a latency period which may range from a few weeks to months (but rarely exceeds 6 months)
- Typical symptoms include:
 - episodes of repeated reliving of the trauma in intrusive memories ("flashbacks") or dreams
 - "numbness" and emotional blunting, detachment from other people, unresponsiveness to surroundings, anhedonia
 - avoidance of activities and situations reminiscent of the trauma.
 - a state of autonomic hyperarousal with hypervigilance, and an enhanced startle reaction

PTSD: acute treatment

- 'watchful waiting'
- Trauma-focused CBT in severe cases
- Individual trauma-focused CBT (or EMDR) for all
- Paroxetine, mirtazapine (primary care)

Obsessive-compulsive disorder (OCD)

- Obsessional symptoms or compulsive acts, or both, must be present on most days for at least 2 successive weeks
- The obsessional symptoms should have the following characteristics:
 - they must be recognized as the individual's own thoughts or impulses;
 - there must be at least one thought or act that is still resisted unsuccessfully;
 - the thought of carrying out the act must not in itself be pleasurable;
 - the thoughts, images, or impulses must be unpleasantly repetitive.

OCD: acute treatment

- SSRIs
- Clomipramine
- Exposure therapy/CBT

Psychotic illnesses

Schizophrenia – positive symptoms

- Auditory hallucinations
- Delusional beliefs
- Thought interference
- Passivity phenomena
- Formal thought disorder

Schizophrenia – negative symptoms

- Affective blunting
- Apathy
- Poverty of thought and speech
- Social withdrawal
- Self neglect

Treatment

- First episode second generation antipsychotic
 - Titrate to response
- If ineffective switch to different antipsychotic
- If ineffective clozapine

- In relapse check compliance/ comorbidity
- If necessary switch to different antipsychotic
 - If ineffective clozapine

Personality disorders

Classification

Represent persistent and characteristic patterns of behaviour

Cluster A Paranoid, Schizoid

Cluster B

Dissocial, Emotionally unstable, Histrionic

Cluster C Anankastic, Anxious (avoidant), Dependent

Borderline personality disorder

- Common in psychiatric settings
- Presence of co-morbidity
- Uncertainty about the usefulness of pharmacological therapies – no evidence
- Target specific symptoms
- Use of psychotherapy

Medication

Pharmacological treatments

- Antipsychotics
- Antidepressants
- Mood stabilisers
- Anxiolytics

Prescribing factors

- EBM
- Comorbidity
- Tolerability
- Medical factors
- Drug interactions
- Discontinuation effects

Antipsychotics

Types of antipsychotics

- First generation 'typicals'
 - Chlorpromazine
 - Haloperidol
- Second generation 'atypicals'
 - Olanzapine
 - Risperidone
 - Quetiapine
 - Clozapine
- Third generation
 - aripiprazole

Drug action

- Excess release of dopamine in the mesolimbic pathway linked to psychotic experiences
- Antipsychotics tend to block D₂ receptors
- Not particularly selective, also block dopamine receptors in other pathways – side effects
- Atypical antipsychotics also block or partially block serotonin receptors

Extrapyramidal side effects

- Dystonic reactions
- Pseudoparkinsonism
- Akathisia
- Tardive dyskinesia

Metabolic side effects

- Hyperprolactinaemia
- Weight gain
- Lipid dysregulation
- Blood sugar abnormalities

Other side effects

- Sedation
- Anticholinergic
- Cardiotoxic
- Increased risk of venous thromboembolism
- Increased risk of stroke
- Neuroleptic malignant syndrome

Antidepressants

Types of antidepressants

- Selective serotonin reuptake inhibitors
- Monoamine oxidase inhibitors
- Tricyclic antidepressants
- Others

Selective serotonin reuptake inhibitors (SSRIs)

- Have broad spectrum anxiolytic efficacy
- Well tolerated
- Easy to manage
- Less drug interactions than older antidepressants
- Generally represent first-line pharmacological treatment

SSRIs: pharmacokinetics

- Inhibit the reuptake of serotonin
- Works on postsynaptic receptors
- Increase levels of serotonin

SSRIs: side effects

- Increased agitation and anxiety
- 'suicidal ideation'
- Gastrointestinal
- Changes in appetite
- Hyponatraemia
- Sexual dysfunction
- Discontinuation syndrome

Monoamine oxidase inhibitors (MAOIs)

- Limited use
- Inhibit the activity of monoamine oxidase, increase availability of monoamines
- Irreversible (Phenelzine)/reversible (Moclobemide)

MAOIs: side effects

- Hypertensive crisis, 'cheese reaction'
- Drug interactions e.g. indirect-acting sympathomimetics
- Sleep disturbances
- Dizziness
- Gastrointestinal complaints

Tricyclic antidepressants (TCAs)

- Certain TCAs efficacious in some anxiety disorders
- 'sedating'/less 'sedating
- Inhibits reuptake of norepinephrine and serotonin
- Greater propensity for adverse effects
- Virtually spares dopamine
- Antimuscarinic
- Antihistaminic (H₁)

TCAs: side effects

- Arrhythmias and heart block
- Dry mouth
- Blurred vision
- Constipation
- Urinary retention
- Sedation
- Hyponatraemia

Others

- Venlafaxine
 - Serotonin and noradrenaline re-uptake inhibitor
 - Nausea, headache, sexual dysfunction, hypertension
- Duloxetine
 - Serotonin and noradrenaline re-uptake inhibitor
- Mirtazapine
 - Increases central noradrenergic and serotonergic neurotransmission
- Reboxetine
 - Selective inhibitor of noradrenaline reuptake

Mood stabilisers

Lithium

- Indications
 - Hypomania/mania
 - Bipolar affective disorder
 - Recurrent depression
- Monitoring
 - Lithium levels
 - Renal function
 - Thyroid levels
 - Calcium levels

Adverse effects and toxicity of lithium

- Side effects
 - Fine tremor, polyuria, thirst
 - Hypothyroidism
 - Hyperparathyroidism
 - Nephrotoxicity
- Toxicity
 - Gastrointestinal effects
 - CNS effects
 - Coma, death

Sodium valproate

- Indications
 - Mania
 - Bipolar affective disorder
- Adverse effects
 - Gastric irritation, nausea
 - Weight gain, peripheral oedema
 - Liver failure
 - Blood abnormalities
 - Teratogenic

Anxiolytics

Anxiolytics

- Buspirone
 - Acts at serotonin receptors
 - Side effects nausea, dizziness, headache, nervousness, excitement
- Pregabalin
 - Works on calcium channels; decreases the release of some neurotransmitters, but increases neuronal GABA
 - Side effects dizziness, drowsiness, visual disturbances, sexual dysfunction, oedema, weight gain
- Benzodiazepines

Benzodiazepines

- Commonly used as an anxiolytic
- Should be reserved for short-term relief
- Some have proven efficacy in the treatment of panic disorder, GAD and social phobia

Benzodiazepines: pharmacokinetics

- Short acting/long acting
- Modifies the release of GABA and potentiates the inhibitory effect of GABA
- Leads to sedatory and anxiolytic effects

Benzodiazepines: side effects

- Paradoxical agitation and aggression
- Dependence and withdrawal
- Drowsiness
- Light-headedness
- Confusion
- Ataxia
- Amnesia



 There is a wide variety of mental disorders and accurate assessment and diagnosis leads to appropriate treatment

• There are multiple efficacious treatments both pharmacological and psychological

 Patient engagement is a key factor to a successful outcome

Thank you